CTI BioPharma announced that the FDA has granted Fast Track designation to pacritinib for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy, or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy.

Pacritinib is currently being studied in patients with myelofibrosis in two Phase 3 clinical trials: one in a broad set of patients without limitations on blood platelet counts, the PERSIST-1 trial, and the other in patients with low platelet counts, the PERSIST-2 trial.

RELATED: Jakafi sNDA Accepted for Polycythemia Vera

Pacritinib is an oral tyrosine kinase inhibitor with dual activity against JAK2 and FLT3.

For more information visit CTIBioPharma.com.